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SUMMARYThe relationships between normal and leukemic stem/progenitor cells are unclear. We show that in80% of
primary human CD34+ acute myeloid leukemia (AML), two expanded populations with hemopoietic progen-
itor immunophenotype coexist in most patients. Both populations have leukemic stem cell (LSC) activity and
are hierarchically ordered; one LSC population gives rise to the other. Global gene expression profiling shows
the LSC populations are molecularly distinct and resemble normal progenitors but not stem cells. The more
mature LSC population most closely mirrors normal granulocyte-macrophage progenitors (GMP) and the
immature LSC population a previously uncharacterized progenitor functionally similar to lymphoid-primed
multipotential progenitors (LMPPs). This suggests that in most cases primary CD34+ AML is a progenitor
disease where LSCs acquire abnormal self-renewal potential.INTRODUCTION
Prospective purification and characterization of stem/progenitor
cells in normal hemopoiesis and leukemia has led to seminal
observations in stem cell and cancer biology. In both humanSignificance
Understanding hownormal stem/progenitor cells are transforme
ical question. Progress depends ondefining relationships betwe
AML initially suggested LSCs might be closely related to norma
quentstudieshavenotclarified the issue.Wenowdefinedistinct,
to normal progenitors, in most primary human AML patients. Th
evolutionary conservation of hemopoietic lineage specification.
pathological LSCs self-renewal and tracking LSCs post treatme
138 Cancer Cell 19, 138–152, January 18, 2011 ª2011 Elsevier Inc.and mouse, multipotent hemopoietic stem cells (HSCs) generate
a hierarchy of proliferative progenitor populations that progres-
sively lose lineage potential as they pass through lineage restric-
tionpoints. Inmouse, the initial lineagedivisionwasoriginally sug-
gested tobe strictly into separate commonmyeloid-erythroid andd into cancer stemcells (CSCs) is a central biological and clin-
enCSCs and normal stem/progenitor cells. Seminal studies in
l hemopoietic stem cells (HSCs) and not progenitors. Subse-
hierarchicallyorganizedLSCpopulationsmostclosely related
e more immature LSC is LMPP-like, providing support for the
Going forward, this work provides a platform for determining
nt, both of which will impact on leukemia biology and therapy.
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Human LMPP and AML LSClymphoid lineages.But recent persuasivedata suggest thatmulti-
potential progenitors (MPPs) initially differentiate into lymphoid-
primed multipotential progenitors (LMPPs, with lymphoid and
granulocyte-macrophage but no megakaryocyte-erythroid
[MkE] potential) and those with MkE potential (Adolfsson et al.,
2005; Arinobu et al., 2007; Lai and Kondo, 2006; Yoshida et al.,
2006). More committed myeloid and lymphoid progenitors lie
downstream (Akashi et al., 2000; Pronk et al., 2007).
Inhuman,HSCsreside in theLin-CD34+CD38-CD90+CD45RA-
compartment and generate Lin-CD34+CD38-CD90-CD45RA-
MPP with lymphomyeloid potential (Majeti et al., 2007).
Downstream of MPP is an incompletely characterized Lin-CD34+
CD38-CD90-CD45RA+ population (termed CD38-CD45RA+
hereafter). More committed Lin-CD34+CD38+ common myeloid
progenitors (CMP), granulocyte-macrophage progenitors (GMP)
and megakaryocyte-erythroid progenitors (MEP) can be sepa-
rated by differential expression of CD123 (IL3RA), CD110 (MPL),
and CD45RA (Edvardsson et al., 2006; Manz et al., 2002).
However, the transitionand lineage restrictionstepsbetweenearly
CD34+CD38- stem/progenitor populations and later
CD34+CD38+ progenitors are poorly defined. More specifically
a human LMPP-like population has not yet been identified.
Acute myeloid leukemia (AML) is the most common adult
acute leukemia. It is genetically heterogeneous and molecular
changes have been important in defining prognosis and therapy
response (for review, see Dohner et al., 2010). Many patients still
die of disease relapse after an initial therapy response, thought to
be due to failure to eradicate chemoresistant leukemic stem cells
(LSCs).
Seminal studies in AML (for review, see Dick, 2008) have led to
the cancer stem cell (CSC) hypothesis, which postulates that
cancers are organized in cellular hierarchies, like normal tissues.
At the hierarchy apex are multipotent, largely quiescent, long-
lived CSCs with marked self-renewal capacity that sustain
disease and differentiate into ‘‘bulk cancer cells.’’ Initial reports
suggested that AML LSCs most closely resemble normal
HSCs, sharing a common limited immunophenotype
(CD34+CD38-) and in being rare populations (Bonnet and Dick,
1997; Ishikawa et al., 2007).
However, the notion that LSCs reside solely in the
CD34+CD38- compartment has been challenged. Modeling of
AML in mice has shown that more mature GMPs produce trans-
plantable LSCs (Cozzio et al., 2003; Huntly et al., 2004; Krivtsov
et al., 2006; So et al., 2003). Specifically, in blast crisis chronic
myeloid leukemia candidate LSCs are GMP-like (Jamieson
et al., 2004). Using more immunodeficient xenotransplant
models, primary human AML cells from both CD34+38- and
CD34+CD38+ compartments have LSC activity (Taussig et al.,
2008; Yoshimoto et al., 2009). Finally, in 20%–40% of primary
AML, >80% of cells are CD34-; in some cases, where the
percentage of CD34+ is <0.5%, LSC activity is present only in
the CD34- compartment or in some cases where the percentage
of CD34+ cells lies between 1%–20%, LSC activity has been de-
tected in both CD34+ and CD34- compartments or only in
CD34+ compartment (Martelli et al., 2010; Taussig et al., 2010).
Moreover, studies to date have not clarified the relationship
between human AML LSCs and normal stem/progenitor popula-
tions. For example, not only does the normal CD34+CD38-
compartment contain HSCs, but it also contains other progeni-Ctors (Majeti et al., 2007). Moreover, as cell surface marker
expression can be aberrant in leukemia, it is not possible to
decipher how LSCs map back onto normal HSCs/progenitors
that share an immunophenotype. More broadly, questions
have been raised about the rarity of CSCs (le Viseur et al.,
2008; Quintana et al., 2008).
Therefore, we set out to clarify the cellular and molecular rela-
tionships between different AML LSC populations within
a patient, between different patients, and finally, between AML
LSC and normal HSC/progenitor populations to definemolecular
pathways important in transformation of normal HSCs/progeni-
tors. We have focused on primary CD34+ AML (where >5% of
cells are CD34+) that comprises the majority of AML. As human
HSC/progenitor cells express CD34, we reasoned the stem/
progenitor hierarchy in CD34+ AML might be more comparable
to normal hemopoiesis.
RESULTS
Immunophenotype of Human CD34+ AML
We compared stem/progenitor-cell immunophenotypes in
primary CD34+ AML and normal control samples. The immuno-
phenotypic gating strategy for normal populations is illustrated in
Figure S1A (available online) and was validated by post FACS-
sort purity analysis (>99% pure) (Figure S1B). In vitro and
in vivo assays confirmed the functional potential of sorted normal
stem/progenitor cells (data not shown; see later in Figure 5). We
immunophenotyped 100 primary AML samples (69 de novo, 20
secondary, 6 relapsed, and 5 refractory AML) spanning FAB
subtypes, cytogenetic and molecular categories (Table 1; Table
S1), and 8 age-matched control marrow samples.
There are two major immunophenotypic groups in CD34+
AML with respect to these markers (Figure 1and Table 1; Table
S1). In 87.8% of 74 AML samples, most Lin-CD34+CD38-cells
are Lin-CD34+CD38-CD90-CD45RA+ (CD38-CD45RA+)
(>90% in most cases) and in 15 randomly selected cases have
low/no CD10 and CD7 expression (data not shown). Hereafter,
this group is named ‘‘CD38-CD45RA+ expanded’’ group (Fig-
ure 1Ab). In this group, most Lin-CD34+CD38+ cells are Lin-
CD34+CD38+CD123+/loCD110-CD45RA+ (hereafter termed
‘‘GMP-like’’ as they share the immunophenotype of normal
GMPs) (Figure 1Ae). Only CD38 is consistently expressed differ-
ently between CD38- CD45RA+ and the GMP-like populations
(data not shown).
Less commonly, in 13.8% of 74 primary AML samples, there is
a dominant Lin-CD34+CD38-CD90-CD45RA- population (>90%
in most cases). Hereafter, this group is named ‘‘MPP-like
expanded’’ group (Figure 1Ac). In this group, there is a corre-
sponding major Lin-CD34+CD38+CD123+/loCD110-CD45RA-
population that shares the immunophenotype of normal CMPs
(Figure 1Af). The major difference in antigen expression between
the two CD34+ populations was CD38. Segregation of AML
cases into CD38-CD45RA+ expanded and MPP-like expanded
groups did not correlate with morphology or genetic markers.
Within these two groups, CD38 expression varies between
AML samples (Figure 1B; Table S1) (Terstappen et al.,
1992). Furthermore, within CD34+CD38- (Figure 1C) and
CD34+CD38+ compartments (Figure 1D; Table S1), there are in-
tersample differences of minor populations. Two possibleancer Cell 19, 138–152, January 18, 2011 ª2011 Elsevier Inc. 139
Table 1. Summary of Clinical, Cytogenetic, and Molecular Features of AML Samples Studied
Diagnosis De Novo AML Refractory AML Relapsed AML 2

AML
Number of samples studied 69 5 6 20
Mean age (yrs) (range) 61 (20-85) 60 (47-68) 67 (57-74) 67 (42-85)
Mean blast count (%) (range) 70% (96-23) 58% (28-82%) 43% (20-75) 40% (20-94)
FAB type Number FAB type available 58 5 6 NA1
M0 6 0 0
M1 15 2 2
M2 11 1 1
M3 1 0 0
M4 14 2 2
M5 11 0 1
Other 10 0 0 0
Cytogenetics Number analyzed 63 5 6 15
Good risk2 8 0 0 0
Intermediate risk2 42 3 2 11
Poor risk2 13 2 4 4
FLT-ITD mutation Number analyzed 54 5 5 15
mutant (ITD/TK)3 14/1 0/0 0/0 2/0
Wild-type 39 5 5 9
NPM mutation Number analyzed 59 5 5 15
Mutant 7 0 0 0
wild type 52 5 5 15
c-kit mutation Number analyzed 53 4 4 15
mutant 1 0 0 0
Wild-type 52 4 4 15
Dominant population in
CD34+CD38- compartment
Number analyzed 58 2 1 13
CD90-CD45RA+ (%) 50 (86.2) 2 (100) 1 (100) 12 (92.3)
CD90-CD45RA-(%) 8 (13.8) 0 0 1 (7.8)
Dominant population in
CD34+CD38+ compartment
Number analyzed 69 5 6 20
CD110-CD45RA+ (%) 58 (84.1) 5 (100) 4 (66.7) 16 (80)
CD110-CD45RA- (%) 11 (15.9) 0 2 (33.3) 3(15)
CD110+CD45RA- (%) 0 0 0 1 (5)
FAB, French-American-British morphologic classification of AML (Bennett et al., 1976). Cytogenetic risk scores are based on the MRC classification
(Grimwade et al., 2010). FLT3, FMS-like Tyrosine kinase 3 gene. ITD, Internal tandem duplication mutation within FLT3 gene. TK, tyrosine kinase
domain mutation within FLT3 gene. NPM1, Nucleophosmin gene. KIT: KIT gene. NA, not applicable.
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Human LMPP and AML LSCreasons for these differences include (1) molecular heterogeneity
between AML samples and (2) different degrees of admixture of
normal and malignant cells. Despite this variability, 87.8% of a
broad range of CD34+ AML samples have one dominant CD38-
CD45RA+ population and a corresponding GMP-like population.
Leukemic Stem Cell Hierarchy in CD38-CD45RA+
Expanded AML
We focused on dissecting which populations had LSC activity
within the major CD38-CD45RA+ expanded group. Previous
data had shown that LSC activity resides in the CD34+ compart-
ment in CD34+ AML (Blair et al., 1997; Bonnet and Dick, 1997).
We assessed LSC activity in 12 patients where we FACS-sorted
both CD38-CD45RA+ and GMP-like populations from each
patient. Six of 12 gave primary engraftment; 5/6 primary and140 Cancer Cell 19, 138–152, January 18, 2011 ª2011 Elsevier Inc.secondary engraftment (Figure 2), and 4/5 tertiary engraftment
(Figure S2D). Samples details are in Table S2. Cells (105) of
each leukemic population from each patient were intravenously
injected into four NOD-SCID mice treated with anti-CD122 anti-
body to remove residual NK-cells (Figure 2A). Cells from both
populations of the six engrafting samples were detected in
marrow of all injected mice with similar levels of engraftment.
FISH analysis from twoAMLpatients with cytogenetic abnormal-
ities, showed 90%–100% of engrafted human cells were
leukemic (Figure 2B; Table S3).
FACS analysis confirmed that for both injected populations
human CD34+ and CD34- cells were detected in mice (Figures
2Ca and 2Cd). In mice injected with CD38-CD45RA+ (Figures
2Cb and 2Cc) and GMP-like (Figures 2Ce and 2Cf) cells, nearly
all human CD34+ and CD34- cells were CD33+CD19-, did not
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Figure 1. Human CD34+ AML Has Expanded Immunophenotypic Progenitor Populations
(A) CD90 and CD45RA expression in CD34+CD38- cells (top) and CD110 and CD45RA expression in CD34+CD38+ cells (bottom) from control sample (left), an
AML sample where CD38-CD45RA+ population is expanded (center CD38-CD45RA+ expanded) and an AML sample where CD45RA- population is expanded
(right MPP-like expanded). Positions of normal HSC, MPP, CD38-CD45RA, CMP, GMP, and MEP are shown.
(B) Patterns of CD38 expression in CD34+ cells in MPP-like expanded AML (top) and CD38-CD45RA+ expanded AML (bottom) with normal control shown
(top left).
(C) Patterns of CD90 and CD45RA expression in CD34+CD38- cells in MPP-like expanded (top) and CD38-CD45RA+ expanded (bottom) AML.
(D) Patterns of CD110 and CD45RA expression in CD34+CD38+ cells in MPP-like expanded (top) and CD38-CD45RA+ expanded (bottom) AML.
Plots are representative examples. Percentage values in quadrants are the average of lin-CD34+ cells for all samples within the group.
See also Figure S1 and Table S1.
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Human LMPP and AML LSCexpress T cell or erythroid markers (CD3 and CD235) and were
blast-like (data not shown), consistent with leukemic myeloid-
restricted engraftment. There was no LSC activity in the CD34-
compartment in 4/4 samples where engraftment from CD34
compartments was noted (Figure S2A). In all four samples, the
percentage of CD34+ cells was >20%. Thus, our data confirm
previous reports showing engraftment from CD34- cells when
>99% of the cells are CD34- (Martelli et al., 2010; Taussig
et al., 2010).
In mice injected with CD38-CD45RA+ cells, a minor fraction of
human CD34+ cells were CD38-CD45RA+ (mean 1.3% for all
patients), consistent with self-renewal of this population (Figures
2Da and 2Db). CD38-CD45RA+ cells also gave rise to GMP-like
cells in vivo (Figure 2Dc). In contrast, when GMP-like cells are
injected in mice, <0.2% of CD34+ cells are CD38-CD45RA+ (Fig-
ure 2Dd). Most injected GMP-like cells retain CD110-CD45RA+Cphenotype (Figure 2De). Taken together, this suggests an
in vivo immunophenotypic hierarchy where a minority of CD38-
CD45RA+ cells self-renew and give rise to GMP-like cells
whereasGMP-like cells cannot give rise toCD38-CD45RA+cells.
Next, we confirmed that CD38-CD45RA+ and GMP-like AML
populations have serial engraftment activity. Human cells (106)
from primary recipients were injected into secondary recipients
(Figure 2E). Engraftment was seen from five of six samples that
showed primary engraftment, with similar secondary engraft-
ment levels between cells taken from primary hosts transplanted
with either CD38-CD45RA+ or GMP-like cells. Lower engraft-
ment level was seen in secondary compared with primary hosts
as previously reported (Bonnet and Dick, 1997). Immunopheno-
typic analysis of engrafted cells showed the fact that >99% of
human cells were CD33+CD19- (Figures S2B and S2C). Most
hCD34+ cells wereGMP-like regardless of whether injected cellsancer Cell 19, 138–152, January 18, 2011 ª2011 Elsevier Inc. 141
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Figure 2. Two Classes of Hierarchically Ordered LSC Activity Coexist in Most AML Patients
(A) Percentage marrow engraftment of hCD45RA+ cells in individual NOD-SCID mice 12 weeks after transplantation from six different AML patient samples.
CD38-CD45RA+ cells (squares) and GMP-like populations (ovals) from each patient were injected into four mice.
(B) FISH analysis of engrafted populations frompatient OX208 (left) andOX268 (right). The cell on the left is fromamouse engraftedwith CD38-CD45RA+ cells and
that on the right engrafted with GMP-like AML cells. In patient OX 208, chromosome 14 is detected by a dual color IGH locus probe and in patient OX268, chro-
mosomes 8 (red signal) and 12 (green) are detected by centromere probes. Cell nuclei are visualized by DAPI counterstain. Twomicrometer scale bars are shown.
(C) A representative example of hCD45/hCD34 expression (left, a and d) hCD19/hCD33 expression in hCD34+(center, b and e), and CD34- (right, c and f popu-
lations from primary engraftedmicewhen transplantedwith CD38-CD45RA+ (top) andGMP-like (bottom) AML cells. Mean percentage values from all six patients
are shown.
(D) A representative example of hCD38 and hCD34 expression on engrafted hCD34+ cells (left, a and d), hCD90/hCD45RA expression in hCD34+CD38- cells
(center, b) andhCD110/hCD45RAexpression (right, c ande) in hCD34+CD38+cellswhenCD38-CD45RA+cells (top) andGMP-likeAML (bottom) cells are injected
into primary engrafted mice. Mean percentage values from all six patients are shown.
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Table 2. Leukemia Initiating Cell Frequency in CD38-CD45RA+ and GMP-Like LSC-Containing Populations
Cell Dose
Sample Fraction 1.00E+02 1.00E+03 1.00E+04 1.00E+05
LICa frequency (95%
confidence interval)
OX208 CD38-CD45RA+ 1/4 1/4 3/3 3/3 1 in 1837 (495-6813)
GMP-like 0/3 0/3 0/4 3/4 1 in 88550 (28014-279897)
OX268 CD38-CD45RA+ 1/4 2/4 4/4 4/4 1 in 1064 (319-3543)
GMP-like 0/4 0/4 3/4 4/4 1 in 8879 (2815-28005)
BIR219 CD38-CD45RA+ 0/4 1/4 2/4 4/4 1 in 10777 (3252-35718)
GMP-like 0/4 0/4 0/4 0/4 >1.00E+05
NOD/SCID mice were used as hosts for samples OX208 and OX268. NSGmice were used as hosts for samples from BIR219. Mice were sacrificed at
10 weeks. Data are reported as number of mice with AML/number of mice receiving transplant.
a LIC, leukemia-initiating cell.
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Human LMPP and AML LSCwere from animals initially injected with CD38-CD45RA+ or
GMP-like LSCs, consistent with differentiation of CD38-
CD45RA+ cells into GMP-like cells but not the reverse.
To assess leukemia initiating cell (LIC) frequency FACS-sorted
CD38-CD45RA+ and GMP-like populations from three different
primary AML samples were assayed (Table 2). The LIC frequency
in the CD38-CD45RA+ compartment varied between 1/1064 to
1/10 777 and was much lower in GMP-like population (1/8879
to >1/100 000). This suggests the CD38-CD45RA+ population
has more potent LSC activity.
Finally, we asked if leukemic cells expanded after injection into
transplanted mice (Table S4). For samples where LIC frequency
had been established, there was a 104–106-fold expansion of en-
grafted cell numbers in primary transplants from injected LSC
pool. In cases where we could only calculate fold expansion of
engrafted cells as a function of injected cells the fold expansion
varied from 1.5–103 in both primary and secondary transplants.
In summary, both CD38-CD45RA+ and GMP-like populations,
within the same patient, have LSC activity. CD38-CD45RA+
LSCs give rise to cells with a GMP-like phenotype but the
converse does not occur.
In Vitro Differentiation of AML LSC Populations
To complement the in vivo observations, we tested the differen-
tiation potential of CD38-CD45RA+ cells and GMP-like popula-
tions in vitro. FACS-sorted CD38-CD45RA+ and GMP-like cells
from five AML patients (ten populations) were cultured and cell
output analyzed (Figure 3). After 4 days, most CD38-CD45RA+
cells remained CD38-CD45RA+ (Figure 3Bb). Remaining input
CD38- cells gained CD38 expression and were GMP-like (Fig-
ure 3Bb). By day 8, most CD38-CD45RA+ cells were GMP-like
and some cells had lost CD34 expression; consistent with differ-
entiation to CD34- blasts (Figure 3Bc). Small numbers of cells
remained CD38-CD45RA+.
After 4 days of culture of most GMP-like cells, retained their
original immunophenotype. Some cells had already lost CD34
expression (Figure 3Bc). By day 8, more cells were CD34- and
though GMP-like cells were still present (Figure 3Bc). There(E) Percentage engraftment of hCD45RA+ cells in marrow of individual seconda
graftedmice initially injectedwith either CD38-CD45RA+ (squares) or GMP-like (ov
recipient mice were injected per population.
See also Figure S2 and Tables S2–S4.
Cwas no differentiation of CD34+CD38+ cells into CD34+CD38-
cells. Thus, in vivo and in vitro data support the notion that the
CD38-CD45RA+ AML population lies upstream of a GMP-like
population at the apex of an LSChierarchy inmost AML samples.
Gene Expression Profiles of AML LSC and Normal
Hemopoietic Stem/Progenitor Cells
We analyzed global mRNA expression profiles from 22 FACS-
sorted CD38-CD45RA+ and 21 GMP-like populations from 27
AML patients. In 18/27 patients we compared expression
profiles between the two populations within each patient,
negating the effect of genetic/epigenetic changes between
patients. We also obtained normal HSC, MPP, CMP, GMP,
and CD38-CD45RA+ populations from four different age-
matched marrow samples. We asked two questions: (1) Are
the two AML LSC populations (CD38-CD45RA+ and GMP-like)
molecularly distinct? (2) Which normal populations are the two
AML LSC populations most similar to at a molecular level?
We used two approaches to determine if expression profiles
for the two AML LSCpopulationswere distinct. First, an unpaired
standard t test (cutoff 0.01) gave a list of genes (360 genes - 458
probes) differentially expressed between 22 CD38-CD45RA+
and 21 GMP-like populations. Expression profiles of this gene
set displayed by 3D Principal Component Analysis (PCA) (Fig-
ure 4A) shows 14/21 of the two populations well separated,
but 7/21 GMP-like populations interspersed with CD38-
CD45RA+ populations. This was confirmed by a paired t test
(cutoff 0.01) applied to CD38-CD45RA+ and GMP-like cells
from the subset of 18 AML cases where both populations were
available from the same patient (917 probes; 748mapped genes)
(Figure S3A) and a moderated t test (p = 0.05) to correct for
multiple testing (54 probes corresponding to 49 annotated
genes) (false discovery rate of 0.05) (Figure S3B). We also exam-
ined the relationship between CD38-CD45RA+ AML and GMP-
like AML populations by hierarchical clustering (Figure S3C).
Most GMP-like and CD38-CD45RA+ AML populations cluster
separately with 5/21 GMP-like and 1/22 CD38-CD45RA+ AML
populations being interspersed.ry transplanted mice transplanted with pooled hCD45+ cells from primary en-
al) cells (each primary leukemia is shown as a different symbol). Four secondary
ancer Cell 19, 138–152, January 18, 2011 ª2011 Elsevier Inc. 143
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Figure 3. In Vitro Differentiation Hierarchy in CD38-CD45RA+ Expanded Group of AML
(A) FACS-sorted CD38-CD45RA+ or GMP-like populations from five AML samples were separately cultured for either 4 or 8 days, and then analyzed by FACS.
(B) (a) Top left, representative example of CD34 and CD38 expression in an AML sample. The purity of CD38-CD45RA+ (center) or GMP-like (right) populations
post-FACS sort and prior to culture is shown.
Below, representative FACS plots of cells when CD38-CD45RA+ and GMP-like populations have been cultured for either 4 days (b) or 8 days (c). Top panel,
CD34/CD38 expression; middle panel, CD90/CD45RA expression in CD34+CD38- cells; bottom panel, CD110/CD45RA expression in CD34+CD38+ popula-
tions. Percentage shown are mean for gated populations for all five AML samples studied.
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Human LMPP and AML LSCTo obtain a quantitative measure of the difference in gene
expression between the two AML LSC populations, we
compared expression between CD38-CD45RA+ and GMP-like144 Cancer Cell 19, 138–152, January 18, 2011 ª2011 Elsevier Inc.populations from the same patient, by a non-parametric (rank
product) method (Figure 4B). With a false discovery rate of
0.05 (pfp = 0.5), 524 mapped genes (567 probes) were
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Human LMPP and AML LSCexpressedmore highly in CD38-CD45RA+ compared with GMP-
like populations (Figure 4Ba). Similarly, 2054 genes (2201
probes) were more highly expressed in GMP-like compared
with CD38-CD45RA+ populations (Figure 4Bb). CD38 was
among the top twenty most differentially expressed genes.
Taken together, CD38-CD45RA+ andGMP-like LSC populations
are molecularly distinct in most cases.
To determine which normal populations the two AML LSC
populations most closely resemble molecularly, we used
ANOVA to establish a 2626 gene set (2789 probes) that maxi-
mally distinguish normal stem and progenitor populations. 3-D
PCA was used to display profiles from the ANOVA curated
gene set from normal populations (Figure 4C). The signature of
normal HSCs was most closely related to the normal MPPs,
with the normal CD38-CD45RA+, CMP and GMP populations
more widely scattered. Individual expression profiles within
normal immunophenotypic populations were tightly clustered.
Next, using this same 2626 gene set, the expression profiles of
22 CD38-CD45RA+ and 21 GMP-like AML populations were
distributed (Figure 4Ca and b). Both AML populations were
more widely dispersed (presumably reflecting genetic/epige-
netic heterogeneity in AML). CD38-CD45RA+ and GMP-like
AML populations mainly clustered around their normal counter-
part population. However, some GMP-like AML populations
were located closer to normal CD38-CD45RA+ cells. Similar
results were obtained with a 1338 Annova gene set (1519
probes) of differentially expressed genes after p-value correction
(Figures S3D and S3E).
We used the same 2626 ANOVA gene set as a classifier to ask
which normal population did each individual AML LSC popula-
tions most closely resemble (Figures 4D–4G). 17/22 (77%)
CD38-CD45RA+ AML populations were classified as normal
CD38-CD45RA+ cells and 5/22 (28%) as normal GMPs. Only
278 probes (272 genes) were required for the classifier. Likewise
for theGMP-like AML populations, 13/21 samples were called as
normal GMP (62%), 7 as normal CD38-CD45RA+ (33%), and 1
sample as normal CMP (5%) using 241 probes (235 genes).
Similar results were obtained by hierarchical clustering using
these same minimum gene sets (Figures S3F and S3G).
Taken together, the gene expression profiles of both AML LSC
populations do not map most closely to normal HSCs but rather
to normal progenitor populations. Given that both CD38-
CD45RA+ and GMP-like LSC serially transplant, we asked if
the expression profiles of these two LSC populations were
enriched for genes suggested to mediate ‘‘self-renewal’’
(Krivtsov et al., 2006). Gene Set Enrichment Analysis (GSEA)
shows significant enrichment for the expression of this ‘‘self-
renewal gene’’ set in CD38-CD45RA+ LSCs compared with
normal CD38-CD45RA+ population (p = 0.014) and GMP-like
LSCs compared with normal GMPs (p < < 0.01) (Figures S3H–
S3K) arguing that LSC populations may have co-opted parts of
a self-renewal-associated program not expressed in normal im-
munophenotypic counterpart progenitors.
Normal CD38-CD45RA+ Population Includes Cells
with Lymphoid Primed Multipotential Potential
Global expression profiles of CD38-CD45RA+ AMLmost closely
resemble normal CD38-CD45RA+ cells. The expression data
also suggested that the normal CD38-CD45RA+ population isCdistinct from other stem/progenitor cells. Previous studies had
not fully shed light on the function of normal CD38-CD45RA+
cells. To investigate the lineage potential of normal CD38-
CD45RA+ cells, we performed colony assays (Figure 5A). Normal
HSC, MPP, CMP, GMP, and MEP populations produced the
expected lineage output. The CD38-CD45RA+ population had
a cloning efficiency of30% and produced granulocyte, macro-
phage, and mixed granulocyte-macrophage colonies. Impor-
tantly, there was no erythroid output. When cells from the initial
colony assay were replated, cells fromCD38-CD45RA+ colonies
had a replating potential intermediate between that of cells from
MPP- and CMP-derived colonies (Figure 5B). CD38-CD45RA+
cells exhibited no megakaryocyte potential, in contrast to
MEPs, CMPs, HSCs, and MPPs (Figure 5C).
The B-lymphoid potential of normal CD38-CD45RA+ cells was
tested in vitro. As a positive control, both HSC and MPP popula-
tions differentiated into myeloid (CD33-expressing) and
B-lymphoid cells (CD19- expressing) cells, whereas CMP/
GMPs only gave rise to CD33+ cells (Figure 5D). CD38-
CD45RA+ cells differentiated into both CD33+ and CD19+ cells
(Figure 5D). The frequency of cells with myeloid, B- and
T-lymphoid potential in the CD38-CD45RA+ population was
determined by limiting dilution analysis (Figures 5D–5H). On
MS5 stroma, 1/3.79 CD38-CD45RA+ cells had myeloid potential
(compared with 1/12.4 GMP cells) (Figure 5E). In conditions that
promote both B cell andmyeloid output, 1/6.38 CD38-CD45RA+
cells differentiated into CD19+ B cells and CD33+ myeloid cells,
whereas 1/95.79 GMP cells showed similar potential (Figure 5F).
B cell andmyeloid potential was always seen together. The T cell
potential of the CD38-CD45RA+ cells was tested in vitro. 1/12
CD38-CD45RA+ cells expressed established T cell markers
CD1a, CD7, and CD3 (Awong et al., 2009) (Figures 5G and 5H)
compared with 1/32 GMP cells. Finally, preliminary data show
that CD38-CD45RA+ cells have NK cell potential.
We also searched for, and failed to find, early TCRd VD, DD, or
DJ and IgHDJ gene rearrangements in CD38-CD45RA+ cells, as
compared with HSC, MPP, CMP, and GMP controls at either loci
in CD38-CD45RA+ DNA or in control DNA (data not shown)
consistent with CD38-CD45RA+ cells being upstream of the
earliest committed lymphoid progenitor.
Expression of Lymphoid- and GM-Specific Genes
in Normal CD38-CD45RA+ Cells
Murine multipotential stem/progenitor cells express low levels of
multiple lineage-affiliated gene expression programs concordant
with their lineage potentials (termed multilineage priming) (Akashi
et al., 2003; Hu et al., 1997; Mansson et al., 2007; Miyamoto
et al., 2002; Ng et al., 2009; Yoshida et al., 2006). As cells pass
through lineage restriction points, losing lineage potential, there is
gradual, concomitant, extinction of lineage-affiliated gene expres-
sion programs. In a refinement of this concept, it has been sug-
gested that there is a cascade of lineage-affiliated transcriptional
signatures, initiated in HSCs and propagated in a differential
manner in lineage-restricted progenitors (Ng et al., 2009)
(Figure 6A).
Whether this also occurs in human hemopoietic stem/progen-
itor cells has not been previously reported. Therefore, we used
quantitative RT-PCR to study expression of select genes shown
in mouse to be representative of lineage-affiliated geneancer Cell 19, 138–152, January 18, 2011 ª2011 Elsevier Inc. 145
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Figure 4. Expression Profiling Shows AML LSC Populations Are Distinct and Most Closely Mirror Normal Progenitor and Not Stem Cell
Populations
(A) 3D principle component analysis (PCA) displaying gene expression profiles using 458 differentially expressed probes (corresponding to 360 mapped genes)
determined by a standard unpaired t test with a cutoff of 0.01 from 22 AML CD38-CD45RA+ (blue spheres) and 21 GMP-like LSC populations (red spheres) were
available from the same patient.
(B) Rank product analysis of probe sets showing either increased expression in CD38-CD45RA+ compared with GMP-like populations (a and vice versa b) using
gene expression profiles from 18 AML patients where both CD38-CD45RA+ and GMP-like population samples were available from the same patient. On the y
axis, the false discovery rate; on the x axis the rank product of the probes. At a false discovery rate of 0.05, numbers of differentially expressed probes are shown
as red lines.
(C) 3-D PCA of expression profiles of four FACS-sorted normal populations (HSCs, black spheres, MPPs, brown spheres, CD34+CD38-CD90-CD45RA+, yellow
spheres, CMPs, pink spheres and GMPs, green spheres) using a 2629 ANOVA gene set (2789 probes) of differentially expressed genes in normal populations.
Positions of 22 CD38-CD45RA+ AML populations (blue spheres) (a, left) and 21 GMP-like AML populations (red spheres) (b, right) are shown.
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Human LMPP and AML LSCexpression programs, in 10 and 100 FACS-sorted normal HSC,
CD38-CD45RA+, GMP, and MEP cells (Figure 6B; Figure S4and
Table S5). The aim was 2-fold. First, to establish if lineage-affili-
ated patterns of gene expression seen in mouse held true in
human. Second, to determine if CD38-CD45RA+ cells ex-
pressed a lineage-affiliated transcriptional program similar to
murine LMPP cells. The gene set chosen for study was based
on previous published data (Akashi et al., 2003; Hu et al., 1997;
Mansson et al., 2007; Miyamoto et al., 2002; Ng et al., 2009;
Pronk et al., 2007; Shojaei et al., 2005; Yoshida et al., 2006)
and our own results.
Consistent with previous data, we found that in ten FACS-
sorted cells, MPL (Buza-Vidas et al., 2006) and HLF (Shojaei
et al., 2005) were most highly expressed in HSCs (Figure 6Ba)
(representative of stem-cell only genes). Using our own expres-
sion data, we confirmed that the stem/progenitor regulator
genes BMI1 and MEIS1 were expressed in HSC and CD38-
CD45R+ cells, with markedly lower expression in GMP and
MEP. Similarly, KIT, IKZF1 (IKAROS) and RUNX1 were also
expressed in HSC and CD38-CD45RA+ cells but also were
expressed in GMP and MEP. Interestingly, HOXA9 and, to
a lesser extent, IL3RA, were expressed principally only in
CD38-CD45RA+ cells.
Turning to myeloid lineage affiliated genes, the early myeloid
genes CEBPA, CSF3R, SPI1 (PU.1) are all expressed in HSCs
with expression retained in CD38-CD45RA+ and GMP cells but
extinguished in MEP (Figure 6Bb). These are reminiscent of
stem cell/myelolymphoid genes (Ng et al., 2009). The next
pattern of myeloid gene expression is seen primarily in CD38-
CD45RA+ and GMP cells (CSFR2A and GFI1) (i.e., restricted
myelo-lymphoid). Finally, the last layer of myeloid gene expres-
sion is exemplified by the late myeloid-specific genes (MPO
and CSFR1), which were mainly expressed in GMPs only (differ-
entiatedmyeloid). The pattern of early lymphoid gene expression
is more focused; CD79A, ETS1, VPREB1, sterile IGHM, FLT3,
NOTCH1, and RUNX3 all maximally expressed in CD38-
CD45RA+ with little expression in other cell types (Figure 6Bc).
Finally, early stem-erythroid-megakaryocyte gene expression
is epitomized by VWF, TAL1, and GATA2 (Figure 6Bd) (all
expressed in HSCs and MEPs). Both VWF and TAL1 were
expressed at much lower levels in CD38-CD45RA+ cells.
GATA2 continues to be expressed in these cells, consistent
with its broader role in progenitor biology (including GMP)
(Rodrigues et al., 2008). The erythroid-specific cytokine receptor
gene EPOR, the erythroid-megakaryocyte transcription factor
GATA1 and late erythroid transcription factor KLF1 show
restricted expression (principally in MEPs). Importantly, none of
these three genes was expressed in CD38-CD45RA+ cells.
Identical patterns of gene expression were obtained when either
10 or 100 FACS sorted cells where studied (Figure S4).
Our gene expression data are consistent with multilineage
priming in primary human stem/progenitors analogous to that
in mouse (Mansson et al., 2007; Ng et al., 2009). Moreover, these(D–G) Classifier analysis using the 2789 ANOVA selected differentially expressed s
the identity of the 22 CD38-CD45RA+ AML populations (D and E) and 21 GMP-lik
entially expressed to the least differentially expressed) are used in the classifier fro
corresponding threshold values. y axis, number of AML samples called.
See also Figure S3.
Cdata are consistent with the lympho-myeloid (GM), but not
erythroid-megakaryocyte, lineage potential of CD38-CD45RA+
cells. Finally, by Gene Set Enrichment Analysis, genes more
highly expressed in human CD38-CD45RA+ cells (Figure 6) are
enriched in murine LMPP (Ng et al., 2009; data not shown).
DISCUSSION
We present the immunophenotype, LSC potential and global
geneexpressionprofilesof a broad rangeofCD34+AMLsamples
using normal stem/progenitor cells as a comparator. The aimwas
to dissect the relationship between normal stem/progenitor cells
and leukemicpopulationswith LSCpotential. Thekeyfindingsare
(1) There are two stem/progenitor immunophenotypic patterns in
CD34+ AML and 80% of cases are accounted for by one pattern
with expansion of CD38-CD45RA+ and CD38+CD45RA+ GMP-
like cells. (2) Within this dominant pattern, both populations
coexist in most patients and have LSC potential. (3) These two
AML LSC populations are molecularly distinct though there is
overlap in global gene expressionprofiles suggesting further puri-
fication of these populations may be possible. (4) In vivo and
in vitro, CD38-CD45RA+ AML cells give rise to a GMP-like popu-
lation but not the converse. Analysis of CD38-CD45RA+ and
GMP-like LSC expression profiles suggests that the former pop-
ulation is enriched for genes upregulated in more immature FAB
type AMLs (M0, M1), whereas the latter for genes expressed in
more mature FAB type AMLs (M2, M4, and M5) (data not shown)
consistentwithCD38-CD45RA+LSCsbeingmore immature than
GMP-like LSC (Figures 2D and 3). (5) Gene expression profiles of
both LSC populations are most similar to their normal immuno-
phenotypic counterpart progenitor populations and not normal
HSCs. (6) The previously poorly characterized normal CD38-
CD45RA+ progenitor population functionally most closely
approximates to a murine LMPP. This population is CD10- (data
not shown) and distinct from the recently described CD10+
MLP (myeloid-lymphoid progenitor) (Doulatov et al., 2010) that
lacks granulocyte potential, an attribute of the murine LMPP.
Recent work abrogating residual immunity in NOD-SCID mice
showed that LSCs were present in both CD34+CD38- and
CD34+CD38+ populations (Taussig et al., 2008). However, it
was unclear how homogeneous LSCs were and what the rela-
tionship was between LSCs and normal stem/progenitor cells
within and between patients.
Therefore, we tested LSC function by intravenously injecting
AML cells in NOD-SCID mice treated with anti-CD122 antibody
and NSG mice. Our data provide compelling evidence that
CD34+CD38- LSCs are most similar, molecularly and immuno-
phenophenotypically, to a LMPP-like progenitor and not HSCs.
We also pinpoint that CD34+CD38+ LSCs are most like
a GMP-like progenitor. In most CD34+ AML patients, both
progenitor-like LSCs coexist and experimentally are hierarchi-
cally ordered. The CD38-CD45RA+ AML population has a higher
LSC frequency compared with GMP-like LSC, consistent withet of probes that separates normal populations. This probe set was used to call
e AML populations (F and G). On the x axis more probes (from the most differ-
m right to left. Top x axis shows numbers of probes used. Bottom x axis depicts
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Figure 5. Normal CD38-CD45RA+ Cells Have Lymphoid Primed Multipotential Myeloid Potential
(A) Myeloid/erythroid colony growth of FACS sorted normal marrow HSC, MPP, CMP, GMP, MEP, and CD38-CD45RA+ populations from five normal samples.
The number of colonies/500 cells plated was scored (mean 1 SD). Colony lineage affiliation is shown by colored bars (right).
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Human LMPP and AML LSChigher self-renewal potential of CD38-CD45RA+ LSCs (Ishikawa
et al., 2007) andCD38-CD45RA+ LSC lying at the apex of an LSC
hierarchy. Thus, we confirm previous findings and suggest
potential resolution to previous open questions.
Our data pointing to the progenitor nature of LSCs are also
consistent with an early report of t(8:21) AMLwhere the leukemic
CD34+CD38- compartment was CD90- (i.e., of progenitor
immunophenotype) in contrast to HSC (CD34+CD38-CD90+)
(Miyamoto et al., 2000). Interestingly, HSCs in remission samples
contained preleukemic mutations suggesting that though LSC
have a progenitor phenotype, disease-initiating mutations may
occur in HSC to produce a preleukemic state.
One important question is whether LSC potential genuinely
exists in more than one population (i.e., both CD38-CD45RA+
and GMP-like populations or other CD34+ populations), or if it
resides in only one population that has not yet been purified to
homogeneity. There are conflicting previous reports from current
immunodeficient mouse models about where LSC potential
resides; some suggest that the LSC potential resides in just the
CD34+CD38- compartment (Ishikawa et al., 2007), whereas
others suggest it is present in both CD34+CD38- and
CD34+CD38+ compartments (Taussig et al., 2008). Though our
gene expression data argue that the two LSC populations are
distinct, the overlap in expression profiles in some patients,
and the fact that CD38 is expressed as a continuous variable,
suggest that additional purification of these two populations
may allow one discrete LSC population to be identified. Our
expression profiles will provide additional testable cell-surface
markers for use in fractionating LSC to homogeneity. Separating
CD38-CD45RA+ and GMP-like AML populations in all patients is
important before re-evaluating their hierarchical relationship,
LSC potential (including LSC frequency by limit dilution) and
molecular constitution.
Our data suggest that the previously uncharacterized normal
CD38-CD45RA+ population contain cells with LMPP-like poten-
tial in vitro. A previous report showed these cells had 5% GM
plating potential in colony assays and limited growth in vitro
(Majeti et al., 2007). We saw more extensive colony potential
only when freshly isolated cells were used or, if previously frozen,
cells were exposed to FLT3L (data not shown). Moreover, our
liquid culture assays were conducted on MS5 stroma. Despite
our in vitro data, there are two caveats. First, B- and T cell and
GM potential needs to be demonstrated from single cells.
Second, we have been unable to demonstrate that human
CD38-CD45RA+ cells have GM and T cell, B cell, and NK poten-(B) Cells from colonies in primary platings (A) were plated in a secondary replating
trated (mean 1 SD).
(C) Megakaryocyte colony growth from FACS sorted normal marrow HSC, MPP,
uals. Mean number (1 SD) of colonies/1000 cells plated is depicted. Colony lin
(D) Representative FACS analysis of CD19/CD33 expression in cells produced fr
cells from four normal marrows.
(E and F) Limit dilution analysis to determine frequency of cells with myeloid (C
CD45RA+ (CD45RA+) (green line) and GMP cells (blue line). One to 500 sorted
stroma/cytokine coculture (144 replicates for each condition).
(G) Limit dilution analysis to determine T cell potential frequency in CD38-CD45RA
samples were tested in individual wells in OP-DL1 stroma/cytokine coculture (36
CD1a, CD7, and/or CD3.
(H) Representative FACS analysis plots of CD1a, CD7 (top) and CD33 and CD3 e
and GMP cells from three marrows.
Ctial in vivo. Normal CD38-CD45RA+ cells engraft very poorly
both in neonatal NOG mice (Majeti et al., 2007) and NOD-SCID
mice treated with anti-CD122 antibody (N.G., P.V., unpublished
data). We find <0.1% engraftment when up to 104 normal CD38-
CD45RA+ adultmarrow or cord blood cells are assayed from 1 to
8 weeks after intravenous or intraosseous injection. In contrast
murine LMPP engraft both marrow and thymus. Most likely this
reflects a limitation of the xenotransplant model and improve-
ments in this assay will be required before robust engraftment
from CD38-CD45RA+ cells is seen. Further experiments will
also be required to show that single CD38-CD45RA+ cells prime
both GM and lymphoid expression programs. Though we could
show this in ten cells, we were unable to technically assess this
at a single cell level (N.G., P.W., A.M., T.E., S.E.J., and P.V.,
unpublished data). We suspect this reflects the relative paucity
of mRNA at the single cell level in human CD38-CD45RA+ cells.
Nevertheless, in vitro data in support of a functional equivalent
to the murine LMPP within human CD38-CD45RA+ cells are
compelling. It is likely that LMPP populations will be widely
conserved in lower vertebrate models and confirmation of this
will allow a careful dissection of mechanisms that allow the
erythroid-megakaryocyte lineage program to separate from the
other hemopoietic lineages through evolution.
An important observation from global expression studies is
that the LSC populations most closely resemble normal progen-
itor populations rather than stem cells or MPPs. This raises the
hypothesis that LSCs may have hybrid characteristics, retaining
the proliferative potential of progenitors, not seen in quiescent
stem cells, and specifically acquiring pathological stem-cell
like self-renewal potential. Support for this comes from expres-
sion profiling of GMP-like LSCs derived either from ectopic
MLL oncoprotein expression or CEBPa mutant mice that
possess a GMP-like expression signature with a superimposed
self-renewal associated (stem-cell like) signature (Kirstetter
et al., 2008; Krivtsov et al., 2006). Interestingly, the self-renewal
associated gene expression signature from MLL-transformed
murine GMP is enriched in primary human AML LSC profiles
(Figure S5). As a next step in highlighting key deregulated self-
renewal associated pathways in LSCs, careful comparison of
primary human AML LSC profiles and normal stem/progenitor
cells from our study with different leukemia-associated self-
renewal associated signatures may be helpful. Ultimately, an
important future goal will be to determine global expression
signatures from LSC and normal stem/progenitor populations
purified to homogeneity.assay. Number of colonies/2500 cells plated from each of the cell type is illus-
CMP, GMP, MEP, and CD38-CD45RA+ populations from three normal individ-
eage affiliation is shown by different colored bars (right).
om bulk culture of FACS sorted HSC, MPP, CD38-CD45RA+, CMP, and GMP
D33+) (E) and mixed B cell (CD19+)/myeloid (CD33+) potential (F) in CD38-
cells from 4 normal marrow samples were tested in individual wells in MS5
+ (green line) and GMP cells (blue line). One to 500 sorted cells from 3 marrow
replicates for each condition). T cell potential was defined as cells expressing
xpression in cells produced from bulk culture of FACS sorted CD38-CD45RA+
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Human LMPP and AML LSCWhat implications do our observations have for AML patients?
As many patients die of disease relapse it will be important step
to monitor the size of distinct leukemic stem/progenitor popula-
tions by combining multi-color immunophenotyping with genetic
analysis to look at clonal architecture. This critical advance can
then be applied to sequential pre- and posttreatment samples
to identify therapy resistant leukemic populations that drive
relapse. One can then ask if such populations have functional
LSC activity in xenografts. Accurate identification of small,
residual, posttherapy relapse-driving populations will be of prog-
nostic value, allowing one to direct patients at high risk of relapse
to alternative therapy and, conversely, spare patients likely to be
cured, from further toxic therapy. Finally, comparison of such
leukemic populations with normal stem/progenitor cells at
a molecular level could provide novel rational targeted therapies,
for example, either monoclonal antibodies directed against
relapse driving population (Majeti et al., 2009) or against path-
ways of abnormal self-renewal.
EXPERIMENTAL PROCEDURES
Patient Samples
Bonemarrow samples from AML patients and patients undergoing orthopedic
surgery with normal blood counts/films were obtained with informed consent
(protocols 06/Q1606/110 and 05/MRE07/74 approved by Oxford Ethics
Committee B). Mononuclear cells were isolated by Ficoll density gradient
within 24–48 hr of collection. CD34+ progenitors were purified using CD34
Microbead Kit and MACS separation columns (Miltenyi Biotec, Bisley UK).
CD34+ and deplete fractions were frozen in 90% FCS/10% DMSO in liquid
nitrogen. Prior to manipulation, frozen CD34+ cells were thawed and left over-
night in Stemspan (StemCell Technologies, Sheffield UK) supplemented with
100 ng/ml of SCF, TPO, and FLT3-L (Peprotech, London).
Xenograft Assay
Experiments were performed both in Universities of Lund and Oxford. In Lund,
they were approved by the University of Lund Animal Welfare Committee. In
Oxford work was conducted in accordance with UK Government Home Office
approved Project License 30/2465. Ten to 14-week-old NOD/SCID or NSG
mice were irradiated 100–125 cGy twice 4 hr apart, 24 hr before 102–105 cells
were injected intravenously. Mice were killed 10–12 weeks later. To abrogate
antibody-mediated cell clearance, NOD/SCID mice were injected intraperito-
neally with 200 mg of anti-CD122 antibody and NSG mice with either
anti-CD122 antibody or IVIG (1 mg/gram body weight) after irradiation. Anti-
CD122 antibody generated from TM-b1cell line was purified using High Trap
Protein G Columns (Amersham Pharmacia, HighWycombe UK). Normal multi-
lineage engraftment was defined by separate CD45+CD33+ and
CD45+CD19+ populations with appropriate scatter characteristics. AML
engraftment was defined by a single CD45+CD33+ population.
ACCESSION NUMBERS
Micorarray data have been deposited in ArrayExpress (www.ebi.ac.uk/
arrayexpress/) with accession number E-TABM-978.Figure 6. Granulocyte-Monocyte And Lymphoid but Not Erythroid-Meg
Cells
(A) Schematic diagram of cellular hierarchy of human stem/progenitor cells and c
iated gene signature (green); myeloid (GM) lineage-affiliated gene signature (blue)
signature (red).
(B) Mean mRNA expression (five replicates ±1 SD) from two pooled normal bone
titative Real-Time RT-PCR in ten FACS-sorted HSC, CD38-CD45RA+, GMP and
(green bars); (b) granulocyte-monocyte lineage cells (blue bars); (c lymphoid line
See also Figure S4 and Table S5.
CSUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and five tables and can be
found with this article online at doi:10.1016/j.ccr.2010.12.012.
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